Latest News

NNOX earnings call for the period ending December 31, 2024.

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel). 

Sabra Healthcare REIT stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 78 to 82 Monday.

Investors should prepare for a 2008-style crisis.Benzinga warns of potential economic crisis predicted by Peter Schiff in 2008. Tariffs, rising interest rates, misguided Fed policy may cause trouble.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

In a welcome move, Stryker stock saw its Relative Strength Rating improve to 72 on Monday, up from 69 a day earlier.

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

In today's session, these stocks are experiencing unusual volume.

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Allspring Global Investments launched two new actively managed ETFs (AGR, ASLV) to provide investors with access to mispriced stocks and value ideas.

Investors continue to brace for volatility ahead of U.S. President Donald Trump's tariff announcement this week. Fundstrat's Tom Lee believes bullish traders will get rewarded.

Tariffs are just the start of the answer to why these three space stocks are going down today.